Literature DB >> 2824719

Inhibition of lymphocyte responsiveness by a glial tumor cell-derived suppressive factor.

T L Roszman1, W H Brooks, L H Elliott.   

Abstract

The results of this study demonstrate the presence of suppressive factor(s) in the tissue culture supernatants of cloned and freshly explanted malignant glioma cells. Culture supernatants obtained from these glial cell lines were demonstrated to have potent suppressive activity as evidenced by their ability to inhibit the proliferative response of normal human peripheral blood lymphocytes induced by phytohemagglutinin and anti-OKT3 monoclonal antibodies. The results further demonstrate the existence of a dose-response relationship between these supernatants and inhibition of mitogen-induced lymphocyte activation. Maximum production of suppressive activity by glial tumor cells was dependent on: 1) the number of tumor cells seeded in culture, 2) whether fetal calf serum was present, and 3) the duration of culture. The production of the suppressive factor(s) was not inhibited by the addition of inhibitors of prostaglandin E synthesis. Experiments designed to determine at what time during lymphocyte activation the suppressive factor was most effective demonstrated that the culture supernatants must be added during the first 24 hours of culture to exhibit inhibitory properties. Finally, proliferation of both the T-helper and T-suppressor/cytotoxic subsets was equally well inhibited by the glial tumor cell culture supernatants.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824719     DOI: 10.3171/jns.1987.67.6.0874

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  12 in total

1.  Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation.

Authors:  T Morimura; C Neuchrist; K Kitz; H Budka; O Scheiner; D Kraft; H Lassmann
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  The alteration of prostaglandin E2 levels in patients with brain tumors before and after tumor removal.

Authors:  Joon-Khim Loh; Shiuh-Lin Hwang; Ann-Shung Lieu; Tzuu-Yuan Huang; Shen-Long Howng
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

3.  Glioblastoma in multiple sclerosis: a case report.

Authors:  Giovanni Frisullo; Agata Katia Patanella; Viviana Nociti; Alessandro Cianfoni; Raffaele Iorio; Assunta Bianco; Alessandro Marti; Pietro Attilio Tonali; Anna Paola Batocchi
Journal:  J Neurooncol       Date:  2009-02-13       Impact factor: 4.130

4.  Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

Review 5.  The role of tregs in glioma-mediated immunosuppression: potential target for intervention.

Authors:  William Humphries; Jun Wei; John H Sampson; Amy B Heimberger
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

6.  Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

Review 7.  Cytokine gene expression within the central nervous system.

Authors:  T Nitta
Journal:  Cell Mol Neurobiol       Date:  1998-12       Impact factor: 5.046

Review 8.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner
Journal:  Semin Immunol       Date:  2008-06-09       Impact factor: 11.130

Review 9.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

Review 10.  Vaccine therapies for patients with glioblastoma.

Authors:  Eli T Sayegh; Taemin Oh; Shayan Fakurnejad; Orin Bloch; Andrew T Parsa
Journal:  J Neurooncol       Date:  2014-08-28       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.